Improving Maternal heAlth by Reducing Malaria in African HIV Women

PHASE3CompletedINTERVENTIONAL
Enrollment

666

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

July 19, 2022

Study Completion Date

June 19, 2023

Conditions
MalariaHIV/AIDSPregnancy Related
Interventions
DRUG

Dihydroartemisinin-piperaquine (DHA-PPQ)

Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision

DRUG

Placebo Oral Tablet

Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision

Trial Locations (2)

Unknown

Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

collaborator

Universität Tübingen

OTHER

collaborator

Centre de Recherche Médicale de Lambaréné

OTHER

collaborator

Medical University of Vienna

OTHER

collaborator

Bernhard Nocht Institute for Tropical Medicine

OTHER_GOV

collaborator

Centro de Investigação em Saúde de Manhiça

OTHER

lead

Barcelona Institute for Global Health

OTHER

NCT03671109 - Improving Maternal heAlth by Reducing Malaria in African HIV Women | Biotech Hunter | Biotech Hunter